MedTrace Logo

Integrating Palliative Care for Patients With Idiopathic Pulmonary Fibrosis and Their Caregivers

NCT02929017 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 140

Last updated 2020-08-07

No results posted yet for this study

Summary

Patients with Idiopathic Pulmonary Fibrosis (IPF) and their caregivers will be randomized to receive this intervention or usual care. The intervention will include information about the disease, self-management strategies, and introduction to advanced care planning in a format with enhanced content available across multiple domains (face-to-face, printed material, digital (tablet) delivered by an interventionist. The usual care group will be provided with routine printed patient education.

At the end of life, IPF patients and their caregivers experience stress, symptom burden, poor quality of life, and inadequate preparedness for end-of-life care planning. The proposed study will measure feasibility, acceptability, and impact of a Supportive Care intervention.

Conditions

Interventions

OTHER

SUPPORT

Members of this group will receive personal, enhanced printed materials, as well as face-to-face support, and digital information provided by the interventionist.

OTHER

Currently Available Printed Material

Subjects will receive their usual standard of care, including currently available printed patient material.

Sponsors & Collaborators

  • National Institute of Nursing Research (NINR)

    collaborator NIH

  • University of Pittsburgh

    lead OTHER

Principal Investigators

  • Kathleen O Lindell, PhD, RN · Dorothy P. and Richard P. Simmons Center for ILD

Study Design

Allocation
RANDOMIZED
Purpose
SUPPORTIVE_CARE
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
45 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-03-23
Primary Completion
2020-06-24
Completion
2020-06-24

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02929017 on ClinicalTrials.gov